• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Beam Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 7:05:11 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BEAM alert in real time by email
    8-K
    0001745999false00017459992025-05-062025-05-06

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 6, 2025

     

    BEAM THERAPEUTICS INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

     

    001-39208

     

    81-5238376

    (State or other jurisdiction

     

    (Commission

     

    (IRS Employer

    of incorporation)

     

    File Number)

     

    Identification No.)

     

     

     

     

     

    238 Main Street

     

     

     

     

    Cambridge, MA

     

     

     

    02142

    (Address of principal executive offices)

     

     

     

    (Zip Code)

     

    (Registrant’s telephone number, including area code): (857) 327-8775

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share

    BEAM

    Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

    The information in this Item 2.02 as well as in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description

     

     

     

    99.1

     

    Press Release Issued by Beam Therapeutics Inc. on May 6, 2025

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    BEAM THERAPEUTICS INC.

     

     

     

     

    Date: May 6, 2025

     

    By:

    /s/ John Evans

     

     

    Name:

    John Evans

     

     

    Title:

    Chief Executive Officer

     

     


    Get the next $BEAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BEAM

    DatePrice TargetRatingAnalyst
    3/28/2025$42.00Neutral → Buy
    BofA Securities
    3/10/2025$40.00Sector Perform → Sector Outperform
    Scotiabank
    1/29/2025Neutral → Overweight
    Cantor Fitzgerald
    11/6/2024$27.00 → $39.00Market Perform → Outperform
    Leerink Partners
    10/16/2024Sector Outperform
    Scotiabank
    7/23/2024$80.00Buy
    H.C. Wainwright
    1/29/2024$38.00 → $40.00Neutral → Overweight
    JP Morgan
    12/15/2023$35.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $BEAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Received Clearance of U.S. IND; Updated Data Expected to be Presented in Second Half of 2025 Ended First Quarter 2025 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities, Including Net Proceeds from $500 Million Financing; Cash Ru

      5/6/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

      New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3) Mean Decrease of 79% in Mutant Z-AAT Observed at Day 28 in 60 mg Cohort (n=3) Fourth Cohort Evaluating 75 mg of BEAM-302 Initiated, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at a Medical Conference in Second Half of 2025 CAMBRIDGE, Mass., April 05, 2025 (GLOBE NEWSWIRE) --  Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alph

      4/5/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

      U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there are no curre

      3/27/25 4:01:00 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Beam Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

      3/28/25 8:10:19 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Scotiabank with a new price target

      Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

      3/10/25 11:54:09 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight

      1/29/25 7:35:38 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

      12/6/24 7:00:00 AM ET
      $ASRT
      $BEAM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

      CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. "We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to o

      12/4/24 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

      CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d

      12/14/23 6:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Fmr Llc claimed ownership of 3,261,955 shares (SEC Form 3)

      3 - Beam Therapeutics Inc. (0001745999) (Issuer)

      4/10/25 9:36:39 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Bellon Christine sold $104,122 worth of shares (5,674 units at $18.35), decreasing direct ownership by 5% to 117,294 units (SEC Form 4)

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      4/3/25 9:53:04 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President Ciaramella Giuseppe sold $136,418 worth of shares (7,434 units at $18.35), decreasing direct ownership by 4% to 190,216 units (SEC Form 4)

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      4/3/25 9:51:57 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Beam Therapeutics Inc.

      10-Q - Beam Therapeutics Inc. (0001745999) (Filer)

      5/6/25 7:30:14 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Beam Therapeutics Inc. (0001745999) (Filer)

      5/6/25 7:05:11 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Beam Therapeutics Inc.

      DEFA14A - Beam Therapeutics Inc. (0001745999) (Filer)

      4/18/25 4:05:05 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/12/24 9:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/7/24 9:56:02 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      10/17/24 11:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Financials

    Live finance-specific insights

    See more
    • Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

      Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

      3/10/25 6:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

      Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort Dosing Completed in Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Initial Clinical Data Expected in 2025 Ended Third Quarter 2024 with $925.8 Million in Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027 Company to Host Conference Call Today, November 5, 2024, at 8:30 a.m. ET CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NA

      11/5/24 6:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

      CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here and under "Events & Presentations" in the Investors section of the company's website at www.beamtx.com. A replay of the webcast will be archived on the com

      10/29/24 6:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care